Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Care Bare Rx vs Enhance MD

An in-depth comparison of two leading GLP-1 Providers

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

7.4

Care Bare Rx

Best for LGBTQ+-inclusive compounded GLP-1 telehealth
★★★3.7

Starting at $199/mo

CompoundedBrandSemaglutideTirzepatide
Visit Care Bare Rx
8.6

Enhance MD

Best for lab-monitored compounded GLP-1 with mandatory video visit
★★★★4.3

Starting at $49/mo

CompoundedSemaglutideTirzepatideQuest Diagnostics Labs Included
Visit Enhance MD

Side-by-Side Comparison

FeatureCare Bare RxEnhance MD
Overall Score7.4/108.6/10
Starting Price$199/mo$49/mo
Editorial Rating3.7 ★ /54.3 ★ /5
Features6 features6 features
States Available039
Compounded✓ Yes✓ Yes
Brand Name✓ Yes
FSA/HSA Accepted
FDA WarningsNoneNone

Pros & Cons

Care Bare Rx

Pros

  • Explicit LGBTQ+-inclusive, 'self-care with pride' positioning — one of the few GLP-1 telehealth brands with this framing
  • All 50 states + Puerto Rico coverage
  • Offers both compounded options ($199/mo) and brand-name Ozempic ($705/mo) — unusual flexibility in the compounded-first telehealth segment
  • Same named medical team as Breeze Meds and Synergy Rx: Dr. Ana Lisa Carr MD (NPI 1689841744) and Dr. Kelly Tenbrink MD (NPI 1346482684)
  • Four named 503A pharmacy partners (Belmar, Strive, Epiq Scripts, Casa Pharma Rx)
  • No FDA warnings or litigation on record

Cons

  • Runs on the same Lion MD clinician network and the same 4 compounding pharmacies as Breeze Meds and Synergy Rx — the three brands are white-labeled storefronts on top of one underlying operation, not three independent providers
  • Compounded medications are not FDA-approved
  • Despite the LGBTQ+ positioning, no formal gender-affirming care pathway or HRT integration is mentioned — the inclusive framing is editorial rather than a clinical specialty
  • Limited accreditation transparency beyond LegitScript claim — no PCAB/ACHC seal on site
  • Pharmacy partners are named but per-batch third-party testing and accreditation details are not independently disclosed

Enhance MD

Pros

  • Baseline and ongoing metabolic lab panels (CMP, lipids, TSH, HbA1c) at Quest Diagnostics every 6 months — a rigor most compounded GLP-1 providers skip entirely
  • Mandatory one-on-one video visit with a US-licensed MD or NP before the first prescription — not a pure-async questionnaire model
  • Three pricing tiers including a combined semaglutide + tirzepatide Elite plan ($322/mo ongoing) — useful for patients plateaued on a single GLP-1
  • LegitScript-certified 503A pharmacy network: Tru Meds Rx, Strive Pharmacy, Pharmacy Hub
  • Aggressive first-month intro pricing: $49 on Core, $99 on Advanced, $189 on Elite
  • Unlimited clinician messaging and dose-adjustment support included

Cons

  • Compounded only — no FDA-approved Ozempic, Wegovy, Zepbound, or Mounjaro option
  • Not available in 10 states: Alabama, Arkansas, Georgia, Hawaii, Louisiana, Mississippi, Missouri, South Carolina, Tennessee, West Virginia
  • Mandatory lab work adds 5–10 days to onboarding vs. async-only competitors
  • No insurance accepted — cash pay, HSA/FSA eligible
  • First-month intro pricing resets to full tier rate after 30 days — the $49/$99/$189 numbers are not the ongoing cost

Our Verdict

Winner: Enhance MDScore: 8.6/10

Enhance MD edges out Care Bare Rx with a higher overall score of 8.6/10 and is particularly strong for lab-monitored compounded GLP-1 with mandatory video visit. Care Bare Rx remains a solid alternative, especially if you're looking for LGBTQ+-inclusive compounded GLP-1 telehealth.

Wegovy®, Ozempic®, and Rybelsus® are trademarks of Novo Nordisk A/S. Mounjaro® and Zepbound® are trademarks of Eli Lilly and Company. All other product names and trademarks referenced on this page belong to their respective owners. WeightLossRankings.org is not affiliated with any pharmaceutical manufacturer. See trademark disclaimer.